Fig. 4From: The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, ChinaComparison of the interval of disease progression between the progressive and stable patients. The interval of disease progression by age (a) and sex (b) by the Kaplan–Meier analysisBack to article page